On this pageJump to a section
A new patient is a cost. A retained patient is a business.
Every telehealth owner I talk to wants to discuss ads. Cost per lead, cost per consult, which creative is working. Fair enough, ads are my trade. But in a program built on monthly care, the dashboard that decides whether you make money is not the ad account. It is the retention curve, and the stretch where it tends to bend is the first few months.
This piece is educational, not clinical or legal advice. I am not telling you how to treat anyone. I am talking about the business side: what a clinic controls once a patient says yes.
Why is retention the whole game in a GLP-1 program?
Because the money is in months, not in the first sale.
A subscription engine turns acquisition spend into an asset only if customers stay, which is the core of my Hims Q2 read. Hims & Hers, for example, says the majority of its online revenue is subscription-based.5 The economics of a clinic are the same at smaller scale: you pay to acquire a patient once and earn the return over the months they remain.
The medical reality adds pressure
In the STEP 1 trial extension, participants who stopped once-weekly semaglutide 2.4 mg and the lifestyle intervention regained two-thirds of their prior weight loss within a year, and the authors concluded that ongoing treatment appears to be required to maintain improvements.4 That is exploratory data from 327 participants in a trial funded by the manufacturer. It is not advice for any individual. But it does mean patients who drop out may lose the benefit they came for, which is a reason to care about retention beyond revenue.
What does the data say about how many patients stay?
Not many, in the real world.
1 in 3
Prime Therapeutics and Magellan Rx Management reported that among 4,066 members, 1 in 3 stayed on their GLP-1 and 27% took their medication as intended. The company noted that low persistence may include shortages as well as side effects.1
How to read it
That study measures people on a medication, not patients in your clinic, and the time frame matters. Do not copy the number into your plan. Use it as a warning that retention is the weak point in the category, and that your own cohort data is what counts.
Why do patients leave?
Four reasons show up in public data and in the logic of the business.
Cost
KFF's May 2024 poll (I used the same data in my compounded semaglutide ad piece) found 54% of people who had taken a GLP-1 drug said it was somewhat or very difficult to afford, and that list prices were $936 to $1,349 before insurance, rebates or coupons.2 When money is tight, a monthly charge is the first thing to go.
Side effects
In the STEP 1 trial, nausea and diarrhea were the most common adverse events and were typically transient and mild to moderate in severity. More participants on semaglutide than placebo stopped treatment because of gastrointestinal events: 4.5% compared with 0.8%.3
Some people leave because of how they feel, and in my experience some leave simply because nobody told them what to expect.
Supply and price shifts
Prime's note about shortages is one example. Another is the price environment. In August 2024, Lilly began offering Zepbound single-dose vials through a self-pay channel at $399 for a four-week supply of the 2.5 mg dose and $549 for the 5 mg dose.7 When patients can compare, a clinic that is vague about its own pricing loses trust fast.
Silence
The quietest cause is also the most fixable. A patient who feels unseen after the first month leaves without telling you why.
How should you communicate titration?
Early, clearly and in writing.
I am not describing a dosing schedule, because that is a clinician's job. I am describing the communication around it. Patients should know, before they start, that the program involves steps, what each step is meant to accomplish, what changes they should report and who to contact.
- Set the expectation at sign-up. One page, plain language: what the first months look like and what is normal to ask about.
- Send a heads-up before each change, so a new step never arrives as a surprise.
- Ask a short question after each change: how are you feeling, anything you want to flag?
- Escalate fast. A message about symptoms goes to a clinician with a clear response time.
- Close the loop. Confirm that the patient got an answer.
What does good side-effect support look like operationally?
Fast, human and measured.
- A named channel for questions, so patients know where to go.
- A response-time standard you track, not just a promise.
- Clinician escalation rules so urgent messages never sit in a general inbox.
- Proactive check-ins at predictable moments rather than only when a patient complains.
- Clear lines between support and clinical advice, reviewed by your medical director.
How should billing be designed to keep patients?
Transparent, flexible and easy to leave.
Say the price plainly
State the monthly price, what it includes and what could change it. Surprise charges are a fast way to turn a satisfied patient into a chargeback.
Offer a pause
A patient who needs a break may cancel entirely if cancel is the only option. A pause keeps the relationship alive. Whether and how you offer one is a clinical and policy decision, so decide it deliberately.
Recover failed payments gently
A declined card is usually an accident, not a decision. A prompt, polite reminder with an easy update link saves more patients than a harsh notice.
Make cancellation simple
The FTC announced its final click-to-cancel rule on October 16, 2024. It requires sellers to make canceling as easy as signing up, with a simple mechanism to cancel and immediately halt charges, and covers almost all negative option programs in any media.6 The agency said most provisions take effect 180 days after Federal Register publication.6 A clean exit is both a legal safeguard and a trust signal. I would build it now.
Retention is not a trick. It is what happens when a patient feels seen, informed and fairly treated every month.
What should you measure?
Cohorts, not averages.
- Retention by start month: of the patients who started in a given month, how many are still active in month one, two, three and six?
- Reasons for leaving, captured in one question at cancellation.
- Support response time and resolution.
- Payment failure recovery rate.
- Net revenue per patient over time, after refunds and costs.
If month three is where your curve bends, you now know where to look. Retention is the last part of the revenue system, and it only works when the earlier parts hand off cleanly. If your funnel, follow-up and reporting are three separate islands, I connect them. Clinical and legal questions belong with your medical director and attorney.
Keep building.Ekai
Questions people ask
Why do patients stop GLP-1 medications?
Public data points to several reasons: cost, side effects and supply. KFF's May 2024 poll found 54% of people who had taken a GLP-1 drug said it was somewhat or very difficult to afford, and Prime Therapeutics said low persistence may include shortages as well as side effects.
How many patients stay on GLP-1 therapy?
A Prime Therapeutics and Magellan Rx study published in the Journal of Managed Care and Specialty Pharmacy found that among 4,066 members, 1 in 3 stayed on their GLP-1 and 27% took it as intended.
What happens when someone stops semaglutide?
In the STEP 1 trial extension, participants who stopped semaglutide 2.4 mg and lifestyle intervention regained two-thirds of their prior weight loss within a year, which the authors say suggests ongoing treatment is required. This is trial data, not medical advice for any individual.
What billing practices help patient retention?
Transparent monthly pricing, advance notice of changes, easy pausing, quick recovery of failed payments and a simple way to cancel. The FTC's final click-to-cancel rule, announced October 16, 2024, requires a simple cancellation mechanism for covered subscriptions.
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
